Named Patient Medicines

Trulicity Dulaglutide Injection is an agonist of the GLP-1 receptor. In some cases, the drug can cause acute renal failure, or worsen chronic renal failure, and may require hemodialysis. While some adverse reactions were reported in patients with no known renal disease, the majority of patients with adverse reactions also had impaired renal function. Therefore, TRULICITY should be used with caution in patients with renal impairment, and renal function should be monitored periodically. Trulicity DULAGLUTIDE Injection Heart rate A limited number of studies have examined the safety and efficacy of Trulicity Dulaglutide Injection in pregnant women. However, these studies have not been conducted in sufficient numbers to draw definitive conclusions. While the drug is generally safe, the possibility of serious adverse effects, including birth defects, should be considered. This medication should be used with caution, especially in women with poorly controlled diabetes. Gastric emptying Despit

  There are few known side effects of LENVIMA 10MG Capsules, but the drug is associated with some adverse reactions. The most common adverse reactions were diarrhea, hypertension, decreased appetite, and decreased weight. In addition, some patients had serious adverse reactions, including dehydration, hypotension, and palmar-plant erythrodysesthesia syndrome. In addition, the drug is associated with a high incidence of hepatic dysfunction and renal failure. LENVIMA 10MG Capsules is not recommended for children younger than two years of age. There is no data to support its safety in children. It is important to follow the directions provided by your healthcare provider to avoid side effects. Furthermore, it is important to note that the drug should only be used for the intended indication. LENVIMA 10MG Capsules is a prescription medicine for the treatment of certain cancers. It is used alone in patients with differentiated thyroid cancer, which has not responded to radioactive iodine.

Empliciti Elotuzumab injection is a medication used to treat multiple myeloma. While it is effective in curing this type of cancer, it can cause side effects. In fact, some patients have reported early death and the occurrence of new cancers. Therefore, patients should consult with a doctor before starting the treatment . EMPLICITI is used to treat multiple myeloma The Empliciti Elotuzumab injection is an immunotherapy drug used to treat multiple myelomoma. It comes in a single-dose vial and is given as an intravenous (IV) infusion. The length of the infusion depends on the amount of the drug in the vial and the body weight of the patient. It is important to discuss the dosage with your healthcare provider, since different dosages will work for different people. It can cause side effects Empliciti Elotuzumab injection is an immunotherapy that targets the hepatic stellate cell antigen receptor. During the injection, patients may experience various side effects. These effects may include

 This article will discuss  Istodax Romidepsinsin Injection. It will also discuss the price of  Istodax Romidepsinsin Injection in India. After that, it will summarize the benefits of ISTODAX and the limitations of its use. Where i buy Istodax Romidepsinsin Injection  Istodax Romidepsinsin Injection is an injectable immunotherapy for the treatment of peripheral T-cell lymphoma (PTCL). This treatment is used for patients with relapsed/refractory disease who have received at least one systemic therapy. The drug is approved only after two or more prior therapies have failed. Patients with PTCL must undergo clinical monitoring to ensure that the drug is working properly. This drug is a bicyclic depsipeptide that is a white powder. Injection kits are provided with 2.2 mL of diluent and ten milligrams of the drug. The injections can be given to patients through an injected line or an infusion bag.  Istodax Romidepsinsin Injection is supplied as a single-dose kit. The sterile lyophilized powd

Before preparing the infusion, read the instructions carefully. Infusions should not be mixed with other medicinal products or intravenous solutions. After the infusion is finished, it is important to flush the IV with sodium chloride 9 mg/ml (0.9%) injection solution to avoid adverse reactions. If there are adverse reactions, reduce the infusion rate. Unused product should be disposed of according to local regulations. Benefits of ARZERRA OFATUMUMAB INJECTION 1000MG 50 The benefits of Arzerra Ofatumumab Injection 1000MG 50ML are numerous, but there are also some risks associated with it. For example, ARZERRA can cause serious infusion reactions, including bronchospasm, dyspnea, and upper respiratory tract infection. If you experience these reactions, you should discontinue the treatment immediately. Arzerra Ofatumumab Injection is an approved drug for patients with CLL who have not responded to previous treatments. It is used in combination with another drug, called chlorambucil (Leuk

If you've been prescribed XELJANZ tofacitiminib for your liver condition, you should understand that it may affect your liver enzymes. If you're taking another medicine that affects these enzymes, you should talk to your healthcare provider. If you have the Hepatitis B or C virus, you should tell your healthcare provider before starting treatment with XELJANZ tofacitinib. This medication can affect your blood and liver, so your doctor may do blood tests to make sure your liver is functioning properly. XELJANZ tofacitinib XELJANZ tofacinib is supplied as tablets in the dosage form of 5 mg to 8 mg. These tablets contain tofacitinib as the active ingredient and are coated with croscarmellose sodium and HPMC 2910/Hypromellose 6cP. They also contain magnesium stearate, titanium dioxide, and triacetin. The recommended daily dose is 5 mg twice a day. XELJANZ is approved for the treatment of moderate-to-severe ulcerative colitis in adults. It is also approved for the treatment of activ

  WHAT IS IDHIFA (Enasidenib)? IDHIFA Medicine IDHIFA is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s). It is not known if IDHIFA is safe and effective in children. IDHIFA may cause serious side effects, including: Differentiation Syndrome. Differentiation syndrome is a condition that affects your blood cells which may be life-threatening or lead to death if not treated. Differentiation syndrome has happened within 1 day and up to 5 months after starting IDHIFA. Check the following symptoms below. ·          fever ·          cough ·          shortness of breath ·          swelling of arms and legs ·          fast weight gain (greater than 10 pounds within a week) ·          bone pain If you develop any of these symptoms of differentiation syndrome, your healthcare provider may start you on a medicine taken by m